{
  "report_rows": [
    {
      "kpi": "Adjusted DEPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5.35 vs. cons $5.29",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic Revenue Growth (Q2 2026, % y/y)",
      "prediction": "MISS",
      "answer": "pred ~5.0% vs. cons ~5.8%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026, $B)",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.09B vs. cons $2.10B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted DEPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$21.90-$22.05 vs. cons $21.95 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Organic Revenue Growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~5%-6% vs. cons ~5.7% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Deltek/DAT/Neptune recovery commentary (no recovery underwritten)",
      "prediction": "UNKNOWN",
      "answer": "guide ~no change (still no recovery assumed) vs. cons expecting gradual H2 improvement (H2 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -4.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -6.5,
  "day5_path": "FADE",
  "day5_rationale": "Even with a DEPS beat, the flagged Q2 organic softness (AS timing, tough TEP comp) plus reaffirmed-not-raised FY guide implies no incremental H2 upside is being underwritten (Deltog/DAT/Neptune recoveries still excluded); in a market primed by Danaher/IBM/Pegasystems-style 'beat-but-cautious' punishments, analysts are likely to trim H2 organic/EPS estimates for the implied deceleration, driving continued multiple compression and estimate fade over the following days rather than a bounce.",
  "day5_confidence": "MEDIUM"
}